{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:17:27Z","timestamp":1787977047778,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K08082"],"award-info":[{"award-number":["19K08082"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00406-026-02264-4","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:39:26Z","timestamp":1779201566000},"page":"3061-3075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Nrf2 activators for schizophrenia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"276","author":[{"given":"Masakazu","family":"Okazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8830-0179","authenticated-orcid":false,"given":"Kenji","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Hamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Nishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9237-2236","authenticated-orcid":false,"given":"Taro","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2264_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","volume":"3","author":"D Addington","year":"1990","unstructured":"Addington D, Addington J, Schissel B (1990) A depression rating scale for schizophrenics. Schizophr Res 3:247\u2013251","journal-title":"Schizophr Res"},{"key":"2264_CR2","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","volume":"39","author":"NC Andreasen","year":"1982","unstructured":"Andreasen NC (1982) Negative symptoms in schizophrenia. definition and reliability. Arch Gen Psychiatry 39:784\u2013788","journal-title":"Arch Gen Psychiatry"},{"key":"2264_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.110","volume":"3","author":"H Bentsen","year":"2013","unstructured":"Bentsen H, Osnes K, Refsum H, Solberg DK, Bohmer T (2013) A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins e\u2009+\u2009c in schizophrenia. Transl Psychiatry 3:e335","journal-title":"Transl Psychiatry"},{"key":"2264_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41380-024-02861-6","volume":"30","author":"HG Bernstein","year":"2025","unstructured":"Bernstein HG, Nussbaumer M, Vasilevska V, Dobrowolny H, Nickl-Jockschat T, Guest PC, Steiner J (2025) Glial cell deficits are a key feature of schizophrenia: implications for neuronal circuit maintenance and histological differentiation from classical neurodegeneration. Mol Psychiatry 30:1102\u20131116","journal-title":"Mol Psychiatry"},{"key":"2264_CR5","first-page":"80","volume":"3","author":"A Bhavani","year":"1962","unstructured":"Bhavani A, Sen N, Punekar B (1962) Impact of ascorbic acid administration on memory, attention, intelligence and motor functions in schizophrenics. Trans India Inst Ment Health 3:80\u201388","journal-title":"Trans India Inst Ment Health"},{"key":"2264_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/wps.21036","volume":"22","author":"A Burschinski","year":"2023","unstructured":"Burschinski A, Schneider-Thoma J, Chiocchia V, Schestag K, Wang D, Siafis S, Bighelli I, Wu H, Hansen WP, Priller J, Davis JM, Salanti G, Leucht S (2023) Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials. World Psychiatry 22:116\u2013128","journal-title":"World Psychiatry"},{"key":"2264_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jpsychires.2025.03.023","volume":"184","author":"H Chen","year":"2025","unstructured":"Chen H, Lu J, Zou T, Teng Z, Qin Y, Wu R, Yan Y, Fu K, Jiang W, Ju Y, Zhu R, Mo J, Lu J, Huang J (2025) Effects of sulforaphane on negative symptoms and cognitive impairments in chronic schizophrenia patients: a randomized double-blind trial. J Psychiatr Res 184:464\u2013472","journal-title":"J Psychiatr Res"},{"key":"2264_CR8","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s11033-020-06041-x","volume":"48","author":"T Clifford","year":"2021","unstructured":"Clifford T, Acton JP, Cocksedge SP, Davies KAB, Bailey SJ (2021) The effect of dietary phytochemicals on nuclear factor erythroid 2-related factor 2 (nrf2) activation: a systematic review of human intervention trials. Mol Biol Rep 48:1745\u20131761","journal-title":"Mol Biol Rep"},{"key":"2264_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1001\/jamapsychiatry.2023.4353","volume":"1","author":"C Correll","year":"2024","unstructured":"Correll C, Citrome L (2024) Pharmacologic treatment of schizophrenia beyond dopamine receptor blockade-has its time come yet? JAMA Psychiatry 1:118\u2013120","journal-title":"JAMA Psychiatry"},{"key":"2264_CR10","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1038\/s41380-021-01374-w","volume":"27","author":"M Cuenod","year":"2022","unstructured":"Cuenod M, Steullet P, Cabungcal JH, Dwir D, Khadimallah I, Klauser P, Conus P, Do KQ (2022) Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia. Mol Psychiatry 27:1886\u20131897","journal-title":"Mol Psychiatry"},{"key":"2264_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00213-005-0117-1","volume":"182","author":"GN Dakhale","year":"2005","unstructured":"Dakhale GN, Khanzode SD, Khanzode SS, Saoji A (2005) Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology Berl 182:494\u2013498","journal-title":"Psychopharmacology Berl"},{"key":"2264_CR12","doi-asserted-by":"crossref","unstructured":"Davis JM, Chen N (2001) The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 62:757-71","DOI":"10.4088\/JCP.v62n1003"},{"key":"2264_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"2264_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.schres.2021.03.018","volume":"231","author":"F Dickerson","year":"2021","unstructured":"Dickerson F, Origoni A, Katsafanas E, Squire A, Newman T, Fahey J, Xiao JC, Stallings C, Goga J, Khushalani S, Yolken R (2021) Randomized controlled trial of an adjunctive sulforaphane nutraceutical in schizophrenia. Schizophr Res 231:142\u2013144","journal-title":"Schizophr Res"},{"key":"2264_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8881770","volume":"2021","author":"EA Ermakov","year":"2021","unstructured":"Ermakov EA, Dmitrieva EM, Parshukova DA, Kazantseva DV, Vasilieva AR, Smirnova LP (2021) Oxidative stress-related mechanisms in schizophrenia pathogenesis and new treatment perspectives. Oxid Med Cell Longev 2021:8881770","journal-title":"Oxid Med Cell Longev"},{"key":"2264_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jamapsychiatry.2024.2890","volume":"82","author":"L Feber","year":"2025","unstructured":"Feber L, Peter NL, Chiocchia V, Schneider-Thoma J, Siafis S, Bighelli I, Hansen WP, Lin X, Prates-Baldez D, Salanti G, Keefe RSE, Engel RR, Leucht S (2025) Antipsychotic drugs and cognitive function: a systematic review and network meta-analysis. JAMA Psychiatry 82:47\u201356","journal-title":"JAMA Psychiatry"},{"key":"2264_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.schres.2010.08.039","volume":"124","author":"C Forbes","year":"2010","unstructured":"Forbes C, Blanchard JJ, Bennett M, Horan WP, Kring A, Gur R (2010) Initial development and preliminary validation of a new negative symptom measure: the clinical assessment interview for negative symptoms (cains). Schizophr Res 124:36\u201342","journal-title":"Schizophr Res"},{"key":"2264_CR18","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/s41380-023-02034-x","volume":"28","author":"B Giangreco","year":"2023","unstructured":"Giangreco B, Dwir D, Klauser P, Jenni R, Golay P, Cleusix M, Baumann PS, Cuenod M, Conus P, Toni N, Do KQ (2023) Characterization of early psychosis patients carrying a genetic vulnerability to redox dysregulation: a computational analysis of mechanism-based gene expression profile in fibroblasts. Mol Psychiatry 28:1983\u20131994","journal-title":"Mol Psychiatry"},{"key":"2264_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","volume":"56","author":"MF Green","year":"2004","unstructured":"Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56:301\u2013307","journal-title":"Biol Psychiatry"},{"key":"2264_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgac024","volume":"3","author":"G Hei","year":"2022","unstructured":"Hei G, Smith RC, Li R, Ou J, Song X, Zheng Y, He Y, Arriaza J, Fahey JW, Cornblatt B, Kang D, Yang Y, Huang J, Wang X, Cadenhead K, Zhang M, Davis JM, Zhao J, Jin H, Wu R (2022) Sulforaphane effects on cognition and symptoms in first and early episode schizophrenia: a randomized double-blind trial. Schizophr Bull Open 3:sgac024","journal-title":"Schizophr Bull Open"},{"key":"2264_CR21","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V (2024) Cochrane handbook for systematic reviews of interventions version 6.5 (updated august 2024). Cochrane"},{"key":"2264_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/JCP.0000000000001324","volume":"41","author":"M Hosseininasab","year":"2021","unstructured":"Hosseininasab M, Zarghami M, Mazhari S, Salehifar E, Moosazadeh M, Fariborzifar A, Babaeirad S, Hendouei N (2021) Nanocurcumin as an add-on to antipsychotic drugs for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 41:25\u201330","journal-title":"J Clin Psychopharmacol"},{"key":"2264_CR23","doi-asserted-by":"publisher","first-page":"7857186","DOI":"10.1155\/2016\/7857186","volume":"2016","author":"CA Houghton","year":"2016","unstructured":"Houghton CA, Fassett RG, Coombes JS (2016) Sulforaphane and other nutrigenomic Nrf2 activators: can the clinician\u2019s expectation be matched by the reality? Oxid Med Cell Longev 2016:7857186","journal-title":"Oxid Med Cell Longev"},{"key":"2264_CR24","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24m15272","author":"J Huang","year":"2025","unstructured":"Huang J, Chen A, Jin H, Liu F, Hei G, Teng Z, Xiao J, Wu R, Zhao J, Davis JM, Shao P, Smith RC (2025) Efficacy and safety of sulforaphane added to antipsychotics for the treatment of negative symptoms of schizophrenia: a randomized controlled trial. J Clin Psychiatry. https:\/\/doi.org\/10.4088\/JCP.24m15272","journal-title":"J Clin Psychiatry"},{"key":"2264_CR25","first-page":"12","volume":"2","author":"S Ingole","year":"2011","unstructured":"Ingole S, Belorkar NR, Waradkar P, Shrivastava M (2011) Role of ascorbic acid supplementation on prevention of olanzapine induced metabolic side effects in schizophrenic patients. Indian J Public Health Res Dev 2:12\u201316","journal-title":"Indian J Public Health Res Dev"},{"key":"2264_CR26","doi-asserted-by":"crossref","unstructured":"Jiang J, Sim K, Lee J (2013) Validated five-factor model of positive and negative syndrome scale for schizophrenia in Chinese population. Schizophr Res 143:38-43","DOI":"10.1016\/j.schres.2012.10.019"},{"key":"2264_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1192\/S0007125000291514","volume":"Suppl","author":"SR Kay","year":"1989","unstructured":"Kay SR, Opler LA, Lindenmayer JP (1989) The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl:59\u201367","journal-title":"Br J Psychiatry"},{"key":"2264_CR28","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s00213-020-05629-2","volume":"237","author":"T Kishi","year":"2020","unstructured":"Kishi T, Miyake N, Okuya M, Sakuma K, Iwata N (2020) N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials. Psychopharmacology 237:3481\u20133487","journal-title":"Psychopharmacology"},{"key":"2264_CR29","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/bdi.13115","volume":"23","author":"T Kishi","year":"2021","unstructured":"Kishi T, Sakuma K, Okuya M, Ikeda M, Iwata N (2021) Omega-3 fatty acids for treating residual depressive symptoms in adult patients with bipolar disorder: a systematic review and meta-analysis of double-blind randomized, placebo-controlled trials. Bipolar Disord 23:730\u2013731","journal-title":"Bipolar Disord"},{"key":"2264_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41398-022-02026-5","volume":"12","author":"T Kishi","year":"2022","unstructured":"Kishi T, Sakuma K, Iwata N (2022) Mitochondrial modulators for obsessive-compulsive and related disorders: a systematic review and meta-analysis. Transl Psychiatry 12:263","journal-title":"Transl Psychiatry"},{"key":"2264_CR31","first-page":"1","volume":"10","author":"S Kouser","year":"2021","unstructured":"Kouser S, Kausar S, Khan S, Ghani DM, Yousef N (2021) Role of antioxidants in the management of schizophrenia: a randomized control trail. J Appl Mech Eng 10:1\u20134","journal-title":"J Appl Mech Eng"},{"key":"2264_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/JCP.0000000000001012","volume":"39","author":"S Kucukgoncu","year":"2019","unstructured":"Kucukgoncu S, Guloksuz S, Tek C (2019) Effects of curcumin on cognitive functioning and inflammatory state in schizophrenia: a double-blind, placebo-controlled pilot trial. J Clin Psychopharmacol 39:182\u2013184","journal-title":"J Clin Psychopharmacol"},{"key":"2264_CR33","volume":"2","author":"PV Magalhaes","year":"2016","unstructured":"Magalhaes PV, Dean O, Andreazza AC, Berk M, Kapczinski F (2016) Antioxidant treatments for schizophrenia. Cochrane Database Syst Rev 2:CD008919","journal-title":"Cochrane Database Syst Rev"},{"key":"2264_CR34","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1192\/bjp.109.459.294","volume":"109","author":"G Milner","year":"1963","unstructured":"Milner G (1963) Ascorbic acid in chronic psychiatric patients\u2014a controlled trial. Br J Psychiatry 109:294\u2013299","journal-title":"Br J Psychiatry"},{"key":"2264_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/WNF.0000000000000344","volume":"42","author":"C Miodownik","year":"2019","unstructured":"Miodownik C, Lerner V, Kudkaeva N, Lerner PP, Pashinian A, Bersudsky Y, Eliyahu R, Kreinin A, Bergman J (2019) Curcumin as add-on to antipsychotic treatment in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 42:117\u2013122","journal-title":"Clin Neuropharmacol"},{"key":"2264_CR36","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1007\/s12035-020-02212-w","volume":"58","author":"G Morris","year":"2021","unstructured":"Morris G, Walker AJ, Walder K, Berk M, Marx W, Carvalho AF, Maes M, Puri BK (2021) Increasing nrf2 activity as a treatment approach in neuropsychiatry. Mol Neurobiol 58:2158\u20132182","journal-title":"Mol Neurobiol"},{"key":"2264_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.703452","volume":"12","author":"AJ Murray","year":"2021","unstructured":"Murray AJ, Rogers JC, Katshu M, Liddle PF, Upthegrove R (2021) Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front Psychiatry 12:703452","journal-title":"Front Psychiatry"},{"key":"2264_CR38","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799\u2013812","journal-title":"Psychol Rep"},{"key":"2264_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The prisma 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"2264_CR40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/ijnp\/pyaa006","volume":"23","author":"A Samaei","year":"2020","unstructured":"Samaei A, Moradi K, Bagheri S, Ashraf-Ganjouei A, Alikhani R, Mousavi SB, Rezaei F, Akhondzadeh S (2020) Resveratrol adjunct therapy for negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial. Int J Neuropsychopharmacol 23:775\u2013782","journal-title":"Int J Neuropsychopharmacol"},{"key":"2264_CR41","doi-asserted-by":"crossref","unstructured":"Solmi M, Seitidis G, Mavridis D, Correll CU, Dragioti E, Guimond S, Tuominen L, Dargel A, Carvalho AF, Fornaro M, Maes M, Monaco F, Song M, Il Shin J, Cortese S (2023) Incidence, prevalence, and global burden of schizophrenia\u2014data, with critical appraisal, from the global burden of disease (GBD) 2019. Mol Psychiatry 28:5319-532","DOI":"10.1038\/s41380-023-02138-4"},{"key":"2264_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41380-022-01832-z","volume":"28","author":"G Wolf","year":"2023","unstructured":"Wolf G, Singh S, Blakolmer K, Lerer L, Lifschytz T, Heresco-Levy U, Lotan A, Lerer B (2023) Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Mol Psychiatry 28:44\u201358","journal-title":"Mol Psychiatry"},{"key":"2264_CR43","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.schres.2017.09.046","volume":"195","author":"JK Wynn","year":"2018","unstructured":"Wynn JK, Green MF, Hellemann G, Karunaratne K, Davis MC, Marder SR (2018) The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: a randomized controlled study. Schizophr Res 195:572\u2013573","journal-title":"Schizophr Res"},{"key":"2264_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/nu8020073","volume":"8","author":"K Zortea","year":"2016","unstructured":"Zortea K, Franco VC, Francesconi LP, Cereser KM, Lobato MI, Belmonte-de-Abreu PS (2016) Resveratrol supplementation in schizophrenia patients: a randomized clinical trial evaluating serum glucose and cardiovascular risk factors. Nutrients 8:73","journal-title":"Nutrients"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02264-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-026-02264-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02264-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:31:30Z","timestamp":1787974290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-026-02264-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2264"],"URL":"https:\/\/doi.org\/10.1007\/s00406-026-02264-4","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest related to the subject of this study as declared by the authors. Interests for the past 3 years are as follows: Mr. Okazaki, Ms. Jo, and Ms. Nagata have nothing to disclose. Dr. Sakuma has received speaker\u2019s honoraria from Janssen, Kyowa, Meiji, Otsuka, Sumitomo, and Takeda and research grants from JSPS KAKENHI (19K17099 and 23K06998) and Japan Agency for Medical Research and Development (JP22dk0307107 and JP23dk0307122). Dr. Hamanaka has received speaker\u2019s honoraria from Meiji, Otsuka, and Sumitomo. Dr. Nishii has received speaker\u2019s honoraria from Meiji, Otsuka, and Sumitomo. Prof. Kitajima has received speaker honoraria from Eisai, Mitsubishi Tanabe, Otsuka, Takeda, MSD, Meiji, Sumitomo, Shionogi, and Viatris, and research grants from a Fujita Health University School of Medicine Research Grant, Grant-in-Aid for Scientific Research(A)(20H00569), and Grant-in-Aid for Scientific Research (C) (21K10702, 22K07627, 24K10721, and 25K10825). Prof. Iwata has received speaker\u2019s honoraria from Sumitomo, Eisai, Janssen, Otsuka, Meiji, Shionogi, Takeda, Yoshitomiyakuhin, and Viatris and research grants from Eisai, Takeda, Sumitomo, and Otsuka. Prof. Kishi has received speaker\u2019s honoraria from Daiichi Sankyo, Shionogi, Eisai, Janssen, Meiji, Otsuka, Sumitomo, Takeda, Mitsubishi-Tanabe, Kyowa, Boehringer Ingelheim, and Viatris and research grants from Eisai, JSPS KAKENHI (19K08082, 23K06998, and 25K10874), Japan Agency for Medical Research and Development (JP22dk0307107, JP22wm0525024, 23dk0307117h0001, and 24dk0307129h0001), and the Japanese Ministry of Health, Labour and Welfare (21GC1018).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for ethical approval was waived in this study because it did not involve any human subjects, and the data retrieved for synthesis was collected from published studies.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}